Venetoclax approved for the treatment of chronic lymphocytic leukemia
On June 8, 2018, the U.S. Food and Drug Administration (FDA) expanded a targeted drug, venetoclax venetoclax (trade name: Venclexta, manufactured by Abbott) for indication. Venetoclax was originally approved by…